O'Shea Hogan Labs flags dropout concerns in retatrutide's phase 3 data
The account calls the up to 28% weight loss impressive but says only about half of participants finished, citing nausea, constipation and skin sensitivity.
Recap by typeshit. Post by @osheahoganlabs on Instagram.